A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

Part of paid clinical trials in Gilbert, Arizona.

Sponsor
Janssen Research & Development, LLC
Study ID
NCT06425991
Phase
PHASE1
Status
Active Not Recruiting

Conditions

  • Relapsed or Refractory Multiple Myeloma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Teclistamab — DRUG
    Teclistamab will be administered subcutaneously.

Study Details

The purpose of this study is to compare the pharmacokinetics (processes by which drugs are absorbed, distributed in the body, and excreted) between teclistamab made from the current commercial manufacturing process (pre-change) and the new manufacturing process (post-change).

Key Dates

Start date
Jun 7, 2024
Status verified
Apr 2026
Primary completion
Feb 28, 2027
Completion
Mar 3, 2027

Study Design

Enrollment
108 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Arm A: Pre-change Teclistamab
    Participants will receive teclistamab monotherapy (made from the pre-change manufacturing process) for all step-up and treatment doses until confirmed progressive disease, death, intolerable toxicity, withdrawal of consent to treatment, or end of the study, whichever occurs first.
  • Experimental: Arm B: Post-change Teclistamab
    Participants will receive teclistamab monotherapy (made from the post-change manufacturing process) for all step-up and treatment doses until confirmed progressive disease, death, intolerable toxicity, withdrawal of consent to treatment, or end of the study, whichever occurs first.

Primary Outcome Measure

Maximum Observed Serum Concentration (Cmax) of First Treatment Dose of Teclistamab [ Time Frame: Cycle 1 (28 days cycle): Predose to Day 7 postdose ]

Locations (7)

Find similar trials in Gilbert, AZ

Related Studies